National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
1969-12-31
This study is a double-blind, placebo-controlled outpatient trial to improve, through the
addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent
individuals currently taking naltrexone (Revia).
Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
1969-12-31
This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption
and crime-related post-traumatic stress disorder in those individuals with both disorders.
This will be a 12-week, placebo-controlled, double-blind outpatient trial.
All subjects will receive cognitive behavioral therapy in addition to a placebo or
sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and
6, 9, and 12 months after study entry.
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2003-01-01
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in
Alaska natives with alcohol dependence. The study will also examine whether a combination of
naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone.
Alaska Native individuals will be recruited into a 16 week outpatient study.
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
Completed
Yale University
Phase 2
2003-01-01
This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in
Alaska natives with alcohol dependence. The study will also examine whether a combination of
naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone.
Alaska Native individuals will be recruited into a 16 week outpatient study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
